The Pharma Data

JULY 27, 2021

AbbVie (NYSE: ABBV) and Calico Life Sciences today announced an extension of their leading-edge collaboration to discover, develop and bring to market new therapies for patients with age-related diseases, including neurodegeneration and cancer. This is the second extension of the collaboration originally established in 2014.

Disease 52

Disease Science Production Therapies 52

The Pharma Data

MARCH 9, 2021

Additional data highlight Lilly’s AD program focused on developing both disease-modifying therapies that slow clinical progression by targeting the underlying causes of AD and novel diagnostics and biomarkers to enable a timely and more accurate diagnosis. About Avid Radiopharmaceuticals.

Disease 40

Disease International Research Therapies 40

The Pharma Data

AUGUST 5, 2021

approval; acquisition of Vividion Therapeutics agreed; start of first clinical study for Parkinson’s cell therapy treatment. Bayer recently formed its own cell and gene therapy platform as part of its transformation strategy for Pharmaceuticals. Group sales increase by 12.9 percent (Fx & portfolio adj.) percent to 1.61

Production 52

Production Pharmaceuticals Science Therapies 52

Drug Discovery World

APRIL 10, 2024

An ICON survey of over 100 drug development professionals in obesity research revealed optimism about future therapies, with a significant shift towards combination treatments for obesity and its comorbidities. Determining the best starting doses and titration patterns is often a goal of early phase clinical development.

Clinical Trials 130

Clinical Trials Trials Therapies Treatment 130

Drug Discovery World

FEBRUARY 15, 2023

Existing therapies have been focused on eliminating the cancer cells and/or on preventing its progression by using a combination of chemotherapy, radiotherapy, and surgical approaches. Genetically modified T cells stimulated with IL2 are now administered as cell therapy for multiple cancer cell types with beneficial results 3,4.

Research 130

Research Therapies Immune Response Clinical Trials 130

Drug Discovery World

MAY 30, 2023

From antibody-drug conjugates and RNA, to CRISPR and CAR-T therapy, DDW asked the drug discovery industry what the most important development in oncology over the last five years has been. Immunopheresis is a ‘subtractive therapy,’ in contrast to alternative drugs that constitute ‘additive’ therapies.

Research 130

Research Targeted Protein Degradation Drugs RNA 130

Drug Discovery World

JUNE 26, 2023

Now, there are many mRNA-based therapeutics in clinical development and mRNA cancer vaccines have been promised by 2030. So which companies are taking the lead in this market?

Vaccine 130

Vaccine Virus Clinical Trials Trials 130

The Pharma Data

FEBRUARY 24, 2022

– Jardiance is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death and hospitalization for heart failure, regardless of ejection fraction. with more than 8 million cases expected by 2030. . with more than 8 million cases expected by 2030.

FDA Approval 52

FDA Approval FDA Hospitals Trials 52

The Pharma Data

NOVEMBER 5, 2020

Lastly, we are proud that our novel antibody cocktail REGN-EB3 recently became the first FDA-approved treatment for Ebola, underscoring the potential of antibody therapies to address deadly infectious diseases.” Updates from the clinical pipeline include: Dupixent ® (dupilumab). Corporate and Business Development Update.

Production 52

Production FDA FDA Approval Trials 52

Drug Discovery World

NOVEMBER 18, 2022

Overall, the WHO’s assessment of antibacterial products in clinical development 4 highlights the lack of activity in the sector, stating that the clinical pipeline and recently approved antibiotics “are insufficient to tackle the challenge of increasing emergence and spread of antimicrobial resistance.” .

Pharmaceutical Companies 130

Pharmaceutical Companies Government Pharmaceuticals Hospitals 130

Codon

MARCH 24, 2024

market with Wegovy will, by 2030, require about one million liters of production capacity. The real cost is clinical development. Cirsium Bio is using plants to produce viral vectors for gene therapy. The total global bioprocessing capacity was estimated at 17.4 We further estimate that supplying just the U.S.

Engineering 87

Engineering Vaccine Production RNA 87